The US FDA has approved Fujirebio Diagnostics’ Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, a blood test for early detection of Alzheimer’s disease in adults aged 55 and older. The test measures plasma levels of pTau217 and β-amyloid 1-42 proteins. The clearance was based on the results from a clinical test of 499 plasma samples. Fujirebio’s new test sets a benchmark for other blood tests to meet, according to analyst Puneet Souda.
Cyber attack on Legal Aid Agency exposed 'significant' data, including criminal records – Sky News
A cyber attack on the Legal Aid Agency compromised significant data, including sensitive criminal records. The breach has raised concerns about data security and privacy,
